The European Society of Cardiology (ESC) HF III Registry provides contemporary data on clinical characteristics and outcomes in patients with HF across Europe and affiliated countries. This analysis assessed in-hospital mortality and 1-year cause-specific outcomes. The analysis was published in the European heart Journal.
Between November 1, 2018, and December 31, 2020, 10,162 patients were enrolled from 220 centres in 41 countries. Of these, 39% presented with acute HF (AHF; median age 70 [62–79] years; 36% women) and 61% had an outpatient HF visit (median age 66 [58–75] years; 33% women). Overall, 58% had HF with reduced ejection fraction (HFrEF), 17% HF with mildly reduced ejection fraction (HFmrEF), and 25% HF with preserved ejection fraction (HFpEF).
In AHF, median hospitalization was 9 (6–14) days, and in-hospital mortality was 5.1% (HFrEF 5.2%; HFmrEF 4.8%; HFpEF 3.4%). Among hospital survivors and outpatients followed for a median 376 (360–432) days, all-cause mortality per 100 patient-years was 19 (AHF HFrEF), 22 (AHF HFmrEF), 16 (AHF HFpEF), 6.6 (outpatient HFrEF), 4.0 (outpatient HFmrEF), and 3.9 (outpatient HFpEF). At least one HF (re-)hospitalization occurred in 44%, 42%, and 36% post-AHF and 21%, 14%, and 18% post-outpatient visits for HFrEF, HFmrEF, and HFpEF, respectively.
In-hospital mortality was 5.1%, higher with lower ejection fraction. One-year mortality and rehospitalization rates remained substantial, particularly following AHF.
